The disaccharide moiety is responsible for the tumor cell targeting properties of bleomycin (BLM). While the aglycon (deglycobleomycin) mediates DNA cleavage in much the same fashion as bleomycin, it exhibits diminished cytotoxicity in comparison to BLM. These findings suggested that BLM might be modular in nature, composed of tumor-seeking and tumoricidal domains. To explore this possibility, BLM analogues were prepared in which the disaccharide moiety was attached to deglycobleomycin at novel positions, namely, via the threonine moiety or C-terminal substituent. The analogues were compared with BLM and deglycoBLM for DNA cleavage, cancer cell uptake, and cytotoxic activity. BLM is more potent than deglycoBLM in supercoiled plasmid DNA relaxation, while the analogue having the disaccharide on threonine was less active than deglycoBLM and the analogue containing the Cterminal disaccharide was slightly more potent. While having unexceptional DNA cleavage potencies, both glycosylated analogues were more cytotoxic to cultured DU145 prostate cancer cells than deglycoBLM. Dye-labeled conjugates of the cytotoxic BLM aglycons were used in imaging experiments to determine the extent of cell uptake. The rank order of internalization efficiencies was the same as their order of cytotoxicities toward DU145 cells. These findings establish a role for the BLM disaccharide in tumor targeting/uptake and suggest that the disaccharide moiety may be capable of delivering other cytotoxins to cancer cells. While the mechanism responsible for uptake of the BLM disaccharide selectively by tumor cells has not yet been established, data are presented which suggest that the metabolic shift to glycolysis in cancer cells may provide the vehicle for selective internalization.
■ INTRODUCTION
The bleomycins (BLM) are a family of glycopeptide-derived antitumor antibiotics first isolated from Streptomyces verticillus.
1,2 Their antitumor activity derives from their ability to effect DNA cleavage in cancer cells 3−6 and probably reflects the propensity of the compounds to effect double-strand DNA cleavage. 7−10 The bleomycins are also tumor-seeking molecules, as demonstrated initially by the use of bleomycins derivatized with radionuclides 11−16 and more recently in cell culture experiments involving bleomycins and BLM carbohydrates conjugated to microbubbles 17 and dyes. 18 Bleomycin-mediated DNA strand scission requires oxygen and a metal ion such as Fe or Cu, which activates BLM for DNA degradation. 19, 20 The DNA degradation process is initiated by the binding of activated BLM to its DNA substrate; 21 the actual chemistry of DNA degradation has been characterized 2,22−24 and shown to involve the rate-limiting abstraction of a H atom from the C-4′ position of a nucleoside deoxyribose moiety. 25 As shown in Figure 1 , the structure of bleomycin (1) includes a disaccharide moiety composed of two unusual sugars, L-gulose and 3-O-carbamoyl-D-mannose. Interestingly, the disaccharide moiety is not essential for DNA cleavage in vitro, as the BLM derivative lacking the disaccharide (deglycoBLM, 2) cleaves DNA with a sequence selectivity and chemistry quite similar to that of bleomycin itself, albeit with somewhat diminished efficiency.
26−31
While the disaccharide moiety of BLM is not essential for DNA cleavage, we have recently demonstrated that the disaccharide is sufficient to recapitulate the tumor cell targeting properties of bleomycin. 18 This suggested that bleomycin could potentially be regarded as a modular system composed of a tumor-targeting agent (the disaccharide moiety) and a tumoricidal agent (deglycobleomycin). Consistent with the need for the disaccharide moiety to effect efficient cellular uptake in tumor cells, we find that deglycoBLM is much less cytotoxic than BLM toward cultured cancer cells. To better define the possible modular nature of bleomycin as an antitumor agent, we have prepared derivatives of deglycoBLM in which the BLM disaccharide is attached to the threonine moiety of deglycoBLM (BLM 3) or to the C-terminal substituent (BLM 6). Also prepared as negative controls were two BLM derivatives related to 3 in which the disaccharide consisted of two anomers of L-gulose attached to 3-Ocarbamoyl-D-glucose or linked to deglycoBLM through the threonine moiety (BLMs 4 and 5).
Evaluation of the analogues for efficiency of DNA cleavage in a plasmid DNA relaxation assay revealed that BLM 6 had potency comparable to deglycoBLM (2) , and that BLMs 3−5 were all significantly less potent. Cytotoxicity testing was carried out in DU145 human prostate cancer cells. In spite of the weak DNA cleavage activity of BLM 3, it was found to be more cytotoxic than deglycoBLM itself. BLMs 4 and 5, having disaccharides different than the tumor-targeting disaccharide present in BLM, were minimally cytotoxic. BLM 6, having the BLM disaccharide attached at the C-terminus, was found to be significantly more cytotoxic than deglycoBLM in spite of its comparable DNA cleavage activity. To verify that the cytotoxicities of the BLM derivatives studied were strongly influenced by cellular uptake, cytotoxic BLMs 1, 2, 3, and 6 were conjugated to the cyanine dye Cy5** (affording 44, 45, 47, and 55, respectively). The dye-labeled compounds were shown to be internalized by DU145 cells, and the efficiency of uptake was in direct proportion to the observed cytotoxicities. These data underscore the importance of the BLM disaccharide for cellular uptake of this class of antitumor agent and suggest that the cytotoxic activity of deglycoBLM is limited by lack of facile cellular uptake.
Also studied in a preliminary fashion was the possible basis for cancer cell selective targeting and internalization by the carbohydrate moiety of bleomycin. Evidence is presented that upregulation of one or more receptors associated with enhanced glycolysis in tumor cells may provide the means by which the bleomycins target tumor cells selectively.
■ RESULTS
Synthesis of Bleomycin Analogues. Bleomycin A 5 was an outdated clinical sample; deglycobleomycin A 5 was obtained by treatment of bleomycin A 5 with HF, followed by purification on reversed-phase HPLC. 32 The syntheses of bleomycin analogues 3−5 were accomplished by first preparing the requisite protected glycosylated threonine derivatives 7−9, respectively ( Figure 2) .
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Synthesis of glycosylated threonine derivative 7 began with preparation of the protected 3-O-carbamoylated mannose derivative 14 (Scheme 1). O-Carbamoylated D-glucal 10 33 was treated with methyl trioxorhenium, urea hydrogen peroxide, and dibutyl phosphate to afford the protected dibutyl phosphate derivatives of 3-O-carbamoyl-β-D-glucopyranose (11) and 3-O-carbamoyl-α-D-mannopyranose (12) in 30% and 27% yield, respectively. 34 The latter was O-acetylated to afford 13 as a colorless oil in 93% yield and then treated with 30, 39, 40 in an overall yield of 12% for the final four steps of the synthesis and HPLC purification (Scheme 3).
A slightly different strategy was used for synthesis of glycosylated threonine 8. Synthesis began from the protected dibutyl phosphate derivative of 3-O-carbamoyl-β-D-glucopyranose (11) described above (Scheme 1). Following acetylation, intermediate 28 was converted to the respective phenylthiopyranoside (29) in 89% yield by treatment with thiophenol and TMSOTf (Scheme S1, Supporting Information). Fmoc-Lthreonine benzyl ester (19) and gulopyranosyl fluoride 16 were treated with Cp 2 ZrCl 2 and AgOTf, affording α-L-gulopyranosyl threonine derivative 30 as a colorless oil in 38% yield. Also formed in the same reaction was β-L-gulopyranosyl threonine derivative 37 (48% yield), which was employed for the synthesis of glycosylated threonine 9 (Scheme S2, Supporting Information). 30, 39, 40 The strategy employed for synthesis of glycosylated threonine derivative 9 (Scheme S2, Supporting Information) was closely analogous to that used for the preparation of 8. β-LGulopyranosylthreonine derivative 37, obtained in the same reaction used for synthesis of 30 (vide supra), was deacetylated to afford 38, the latter of which was combined with phenylthiopyranoside 29 in the presence of N-iodosuccinimde and AgOTf, affording glycosylated threonine 39 as a colorless foam in 63% yield. Desilylation and peracetylation gave 41 as a colorless foam in an overall yield of 72%. Replacement of the Fmoc protecting group with a Boc group was effected in 68% yield, and 42 was debenzylated by hydrogenolysis over Pd(OH) 2 /C, providing 43 as a colorless solid in 97% yield. Reinstallation of the Fmoc protecting group then provided 9 in 70% overall yield from 43. Intermediate 9 was converted to BLM analogue 5 by analogy with the synthesis of BLM 3 from intermediate 7 (cf Scheme 3). 30, 39, 40 Synthesis of BLM analogue 6 was accomplished by use of the peracetylated BLM disaccharide 25. The anomeric position of the gulose moiety was selectively deacetylated via the agency of the acetate salt of hydrazine to afford 26 in 70% yield, and the disaccharide was then activated as the p-nitrophenylcarbonate derivative (27) (Scheme 4). Condensation with the Cu(II) salt of deglycoBLM A 5 then afforded a carbamate linkage with the C-terminal substituent, and subsequent deacetylation and demetalation provided BLM 6 in 39% yield.
Biochemical and Biological Evaluation of Bleomycin Analogues. Shown in Figure 3 double-strand DNA cleavage. DNA cleavage by BLM 6 was also studied and the results are shown in Figure 4 . While Fe(II)· BLM 6 was less potent at relaxing plasmid DNA than Fe(II)· BLM A 5 , it produced slightly more form II DNA than Fe(II)· deglycoBLM A 5 and more form II DNA than the Fe(II) chelates of BLM derivatives 3, 4, or 5. Thus, BLM analogues 3−6 were all capable of DNA strand scission, but 6 was the most potent.
BLMs 1−6 were tested for their cytotoxicity toward cultured DU145 human prostate cancer cells ( Figure 5 ). The cells were incubated for 24 h in the presence of four different concentrations of each BLM derivative. Cytotoxicity was determined by use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as a vital dye. As anticipated, BLM A 5 was the most potent of the derivatives tested, presumably reflecting both its efficient cleavage of DNA (Figures 3 and 4) and the presence of the BLM saccharide moiety, which has been shown to enable tumor cell targeting and uptake.
18 DeglycoBLM A 5 , lacking the tumor-targeting disaccharide, was cytotoxic to DU145 cells but much less so than BLM A 5 . BLM 3, which has the same disaccharide moiety as BLM itself, was slightly more cytotoxic to cultured DU145 cells than deglycoBLM, in spite of the fact that it is slightly less potent in DNA cleavage (cf. Figures 3 and 4) . Bleomycin derivatives 4 and 5, which are isomeric with 3 but do not contain the same disaccharide as BLM, were only very weakly active as cytotoxins. Compound 6, containing the BLM disaccharide attached to the C-terminal substituent, was less cytotoxic than BLM A 5 but significantly more cytotoxic than deglycoBLM or BLM 3. Thus, the presence of the BLM disaccharide, attached to either of two positions on deglycoBLM other than the natural linkage via β-hydroxyhistidine, resulted in enhanced cytotoxicity. The rank order of cytotoxicities of BLMs 1, 3 and 6 was the same as the order of their potencies of DNA cleavage.
To provide additional evidence in support of the basis for expression of cytotoxicity by glycosylated deglycoBLMs, the four cytotoxic derivatives were conjugated to the cyanine dye Cy5** ( Figure 6 ). As shown in Figure 7 , the dye-labeled conjugate of BLM 1 (44) was internalized the most efficiently, while uptake of dye-labeled deglycoBLM 2 (45) was the least efficient. The dye-labeled conjugate of BLM 6 (55) was internalized more efficiently than the dye-labeled conjugate of BLM 3 (47) but less efficiently than that of BLM 1 (44) . Thus, the rank order of uptake of these conjugates was precisely the same as the rank order of observed cytotoxicities toward DU145 cells.
In an effort to identify the cellular receptor(s) for BLM and its sugars, we considered the possible involvement of metabolic events characteristic of cancer cells, notably the shift to glycolysis for ATP production and away from mitochondrial oxidative phosphorylation. 42 In an effort to mimic this process in normal cells, normal lung WI-38 cells and normal kidney CCD-1105 KIDTr cells were treated with a sublethal dose of the mitochondrial complex I inhibitor rotenone 43 for 24 h to force the cells to use glycolysis to a greater extent. As shown in Figure 8 , following rotenone treatment, both cell lines exhibited the same enhanced update of BLM-Cy5** (44) as did the numerous cancer cell lines we have studied.
18
The facilitative glucose transporter GLUT1 is known to be inducible 44 and is subject to inhibition both by cytochalasin B 45 and phloretin, 46 although neither of these compounds is specific for this receptor. As shown in Figure 9 , both of these known GLUT1 inhibitors effected substantial and dosedependent inhibition of BLM-Cy5** binding/uptake in SW-480 colon cancer cells.
■ DISCUSSION
The present study was designed to define the contributions of the carbohydrate moiety of bleomycin to the DNA-cleaving and cytotoxic actions of this clinically used antitumor antibiotic. DeglycoBLM, the bleomycin analogue lacking the carbohydrate moiety, has been studied fairly extensively and shown to cleave duplex DNA by the same chemistry as BLM and with similar sequence selectivity. 29, 47 However, the potency of supercoiled DNA relaxation by deglycoBLM is 2−3-fold less than for BLM, and much less double-strand cleavage is apparent for deglycoBLM.
26−31 Two studies in which the disaccharide moiety was replaced with a single sugar afforded BLM analogues with diminished potency of DNA cleavage 48, 49 as well as a lesser ability to cleave RNA. 49 Thus, the disaccharide moiety attached to BLM via β-hydroxyhistidine significantly potentiates DNA cleavage and enables double-strand DNA cleavage and RNA cleavage. The present study in DU145 prostate cancer cells revealed that deglycoBLM was significantly less cytotoxic than BLM. It was initially unclear whether this diminished cytotoxic potential of deglycoBLM was due to diminished potency of DNA cleavage, lack of significant double-strand cleavage, or lack of tumor cell targeting and uptake. The recent study from our laboratory documenting tumor targeting and uptake by the disaccharide moiety itself 18 underscores the ambiguity intrinsic to defining the role(s) of the BLM disaccharide.
In order to gain insights into possible roles of the disaccharide, the present study considers the possibility that BLM may be modular in nature, composed of a carbohydrate moiety responsible for tumor targeting and uptake and an aglycon that mediates DNA strand scission. This hypothesis was tested by preparing analogues of BLM in which the disaccharide moiety is attached to BLM through structural elements other than the β-hydroxyhistidine moiety. If BLM actually is modular in nature, it might be anticipated that the disaccharide would still target tumor cells and the aglycon would still exert a cytotoxic effect via DNA strand scission in spite of the altered relative orientations of these two structural elements.
Analogue 3 differs from BLM in that it has the normal BLM disaccharide attached through the threonine moiety. This position has been shown to be reasonably tolerant of substitution, 50−52 although it has also been demonstrated that threonine is spatially close to a structural element in BLM that requires a specific conformation for optimal expression of DNA cleavage activity.
52−54 Analogues 4 and 5, containing disaccharides isomeric to those in 3, were anticipated to have DNA cleavage activities comparable to 3 but to lack any tumor targeting/uptake properties. Finally, BLM analogue 6 has a disaccharide moiety identical with that of BLM but attached to the end of the C-terminal substituent by means of a carbamate linkage. It was anticipated that the disaccharide itself would have little effect on the efficiency of DNA cleavage, such that the potency of DNA cleavage should be similar to that of deglycoBLM A 5 (2) .
Synthesis of BLM Analogues. BLM analogues 3−5 were prepared by solid-phase synthesis essentially as described 30, 39, 40 using glycosylated threonine building blocks 7−9, respectively. The synthesis of key intermediate 7 was accomplished by condensation of the activated disaccharide (18) with Fmocthreonine benzyl ester (19) . This was converted to 7 in several steps by the introduction of appropriate protecting groups for solid-phase synthesis (Scheme 2). A slightly different strategy was employed for the synthesis of 8 and 9. Condensation of gulopyranosyl fluoride 16 with Fmoc-threonine benzyl ester (19) afforded a mixture of anomeric gulopyranosylthreonine derivatives 30 and 37 (Schemes S1 and S2, Supporting Information), which were separated by flash chromatography on a silica gel column. Intermediate 30 eluted subsequent to 37 from the silica gel column when washed with 2:1 hexanes− ethyl acetate. Following deacetylation to afford 31, treatment with phenylthioglucoside 29 afforded key intermediate 32 (Scheme S1, Supporting Information). Protecting group optimization then gave intermediate 8. The same strategy was used to convert 37 to disaccharide 39, the latter of which was converted to intermediate 9 (Scheme S2, Supporting Information). Compounds 7−9 were then employed for the syntheses of BLM analogues 3−5 by solid-phase synthesis (Scheme 3). 30, 39, 40 BLM analogue 6 was accessible by modification of deglycoBLM A 5 . DeglycoBLM A 5 was treated with 1 equiv of Cu 2+ to form a chelate in which the amino group of the β-aminoalanineamide substituent is rendered unreactive, 55, 56 permitting the primary amine at the C-terminus of deglycoBLM A 5 to react selectively with electrophilic species. Thus, condensation of Cu(II)·deglycoBLM A 5 with the activated p-nitrophenylcarbonate derivative of BLM disaccharide (27) afforded Cu(II)·BLM 6, which was demetalated and purified by reversed-phase HPLC (Scheme 4).
Evaluation of BLM Analogues. As shown in Figure 3 , Fe(II)·BLMs 3, 4, and 5 all effected the relaxation of supercoiled pBR322 plasmid DNA when used at 4 μM concentration, but they did so rather weakly and without producing detectable double-strand cleavage. Thus, unlike BLM itself, which cleaves DNA more potently than deglycoBLM and with more associated double-strand breaks, introduction of the BLM disaccharide by attachment at the threonine moiety actually diminished DNA strand scission. This is consistent with reports that the linker region of BLM must assume a specific conformation to exhibit optimal DNA cleavage properties; 52−54 the introduction of a large substituent to threonine in the form of the disaccharide presumably precludes folding into the conformation optimal for DNA cleavage. For Fe(II)·BLM 6, more significant DNA nicking was observed, as shown in Figure 4 . This experiment employed supercoiled pSP64 plasmid DNA, also demonstrating that the source of the plasmid DNA was unimportant. The potency of cleavage was slightly greater than that of Fe(II)·deglycoBLM A 5 . Furthermore, as might have been anticipated, introduction of the BLM saccharide within the C-terminal substituent had no effect on the extent of double-strand cleavage by 6 relative to deglycoBLM.
The cytotoxicity of the modified BLMs was studied in comparison with that of BLM A 5 and deglycoBLM A 5 , by use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as a vital dye to assess cell viability. As shown in Figure 5 , deglycoBLM A 5 was significantly less cytotoxic than BLM A 5 , potentially due to multiple factors including its lower potency as a DNA cleaving agent, its propensity to produce fewer double-strand DNA breaks, and the absence of the tumor cell targeting disaccharide moiety. BLM analogue 3 was slightly more cytotoxic than deglycoBLM A 5 at the highest two concentrations tested. Since this analogue cleaves DNA no more potently than deglycoBLM A 5 , its greater cytotoxic potential must be due to the tumor selectivity and uptake associated with the presence of the BLM disaccharide in 3, even though the disaccharide is present in a "non-native" position. Consistent with this interpretation was the very weak cytotoxic activity of BLM analogues 4 and 5, which have disaccharides in the same position as 3 and cleave DNA as well as 3 but whose disaccharides lack tumor-targeting properties.
BLM analogue 6, having the BLM disaccharide appended to the C-terminal substituent, was intermediate in cytotoxicity between BLM A 5 and deglycoBLM A 5 . Since BLM 6 cleaved DNA with a potency only slightly greater than that of deglycoBLM A 5 and produced no more double-strand cleavage than deglycoBLM A 5 , its greater cytotoxicity can most logically be ascribed to the presence of the tumor-selective BLM disaccharide. This was true in spite of the fact that the disaccharide was attached to the molecule in a position quite different than that in BLM itself. This thesis was tested by preparing cyanine dye-labeled conjugates of the cytotoxic BLMs (44, 45, 47, and 55, corresponding to BLMs 1, 2, 3, and 6, respectively) ( Figure 6 ). As shown in Figure 7 , the efficiencies of cellular uptake of these four BLM analogues were in precisely the same order as their cytotoxic potencies.
In the aggregate, these results strongly support the conclusion that BLM is modular, consisting of an aglycon responsible for DNA cleavage, connected to a tumor-selective disaccharide. It may be noted that the foregoing analysis presumes that all of the BLM derivatives studied kill DU145 cells by the same mechanism involving DNA cleavage. While there is no direct evidence in support of this assumption, it may be noted that a study of the relative potencies of DNA cleavage and cellular cytotoxicity of a number of BLM analogues failed to indicate a strict correlation between potency of DNA cleavage in vitro and cellular cytotoxicity but provides some general support for this assumption. 6 The cytotoxicity of BLM, which is believed to form the basis for its antitumor activity, is often attributed to its ability to mediate double-strand breaks in DNA. While less potent than BLM A 5 as cytotoxic agents, deglycoBLM A 5 (2) and BLMs 3 and 6 all mediated killing of cultured DU145 cells. The potency of the three compounds as cytotoxins was strongly dependent on the presence of the BLM disaccharide moiety somewhere in their structure, and on their potency of supercoiled plasmid DNA relaxation. However, all three compounds exhibited minimal double-strand cleavage of plasmid DNA. An interesting issue not addressed in the present study is whether BLMs such as 2, 3, and 6 possess a mechanism for doublestrand cleavage of chromatin, which is not apparent when simpler DNAs are used as substrates. A recent report from our laboratory suggests a mechanism by which this might occur. 57 Specifically, we have shown that DNAs strongly bound by Fe· BLMs undergo double-strand cleavage predominantly by a novel mechanism involving closely spaced independent singlestrand cleavages. It may well be the case that such doublestrand cleavage reactions constitute the molecular basis for antitumor activity of BLM. Such double-strand cleavage reactions would not be apparent in the analysis provided in Figures 3 and 4 .
The broad selectivity for tumor cells noted for BLM and its sugars suggests that the targeting must involve some process common to all or most cancers. One well-known characteristic of tumor cells is the Warburg effect, that is, the propensity of tumor cells to produce increased amounts of ATP via glycolysis rather than by mitochondrial oxidative phosphorylation. 42 The shift to glycolysis is accompanied by upregulation of glucose transporters 44 to provide the greater amounts of glucose required to support increased glycolysis. In fact, treatment of two normal cell lines with the mitochondrial complex I inhibitor rotenone forced these cells to utilize increased glycolysis in the same fashion as tumor cells and resulted in their greatly enhanced ability to incorporate BLM-Cy5** (44) (Figure 8 ). In support of the possible involvement of glucose transporters in the binding and uptake of BLM (sugars), it was found ( Figure 9 ) that GLUT1 inhibitors cytochalasin B and phloretin mediated dose-dependent inhibition of the binding/ uptake of BLM-Cy5** (44) by SW-480 colon cancer cells. At least one sugar transporter (GLUT5) has been reported to facilitate the cellular uptake of a simple sugar (fructose) conjugated to a cyanine dye (Cy5.5). 58 
■ CONCLUSIONS
The effect of adding the BLM disaccharide to different positions of deglycoBLM was studied. Attachment to the β-hydroxyhistidine moiety, as in the natural product, significantly potentiated both DNA cleavage and cytotoxicity toward cultured DU145 human prostate cancer cells. When the BLM disaccharide was attached to the threonine moiety, DNA cleavage activity was significantly diminished but the cytotoxicity toward DU145 cells was enhanced nonetheless, arguing that the cytotoxicity of deglycoBLM is severely limited by lack of cellular uptake. Two analogues in which close structural analogues of the BLM disaccharide were attached to threonine exhibited similar DNA cleavage but essentially no cytotoxicity, consistent with the thesis that both facilitated uptake and DNA cleavage are essential to the expression of cytotoxicity by bleomycin. An analogue having the BLM saccharide attached to the C-terminal substituent exhibited relatively good DNA cleavage and cytotoxicity, entirely consistent with the need for efficient uptake and DNA cleavage as prerequisites for cytotoxicity. The relationship between (BLM sugar-mediated) cell uptake and cytotoxicity was confirmed by measuring the actual extent of incorporation of cytotoxic BLM analogues following conjugation to a cyanine dye. These findings confirm that BLM is a modular molecule, composed of a tumor cell targeting moiety (the saccharide) attached to a cytotoxic DNAcleaving domain (the BLM aglycon). This finding implies that the BLM saccharide moiety may be able to deliver other cytotoxins selectively to tumor cells. The uptake mechanism is suggested to involve one or more cell surface receptors involved in glucose transport in tumor cells, which are upregulated in tumor cells to support their enhanced use of glycolysis. 4,6-Di-tert-butyl-O-silylene-2-O-acetyl-3-O-carbamoyl-1-phenylthio-α-D-mannopyranose (14) . To a cooled (−78°C) solution containing 2.62 g (4.38 mmol) of 13 and 4 Å molecular sieves in 15 mL of CH 2 Cl 2 were added sequentially 711 μL (723 mg, 6.57 mmol) of thiophenol and 1.98 mL (2.43 g, 10.9 mmol) of TMSOTf. The reaction mixture was allowed to warm to ambient temperature and was quenched by the addition of 10 mL of saturated aqueous NaHCO 3 . The reaction mixture was diluted with 100 mL of CH 2 2-O-Acetyl-3,4,6-tri-O-benzyl-α,β-L-gulopyranosyl Fluoride (16) . To a cooled (0°C) solution containing 1.00 g (1.97 mmol) of 3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)-α-L-gulopyranose (15) 35 in 20 mL of dry CH 2 Cl 2 was added dropwise 287 μL (350 mg, 2.17 mmol) of DAST. The solution was allowed to warm slowly to ambient temperature and stirred for 3 h. The solution was then diluted with 50 mL of CH 2 Cl 2 and poured into 50 mL of ice water. The aqueous layer was extracted with three 25 mL portions of CH 2 Cl 2 , and the combined organic extract was washed sequentially with 50 mL of H 2 O, 50 mL of saturated aqueous NaHCO 3 , and 50 mL of brine and then dried (MgSO 4 ) and concentrated under diminished pressure. of AgOTf in the dark. The reaction mixture was allowed to warm to −5°C and was quenched with 10 mL of saturated aqueous NaHCO 3 90 s after the color changed from colorless to deep purple. The reaction mixture was diluted with 25 mL of CH 2 Cl 2 and poured into 25 mL of saturated aqueous Na 2 S 2 O 3 . The aqueous layer was extracted with three 50 mL portions of CH 2 (Scheme 3) 39,40 was added a 20% solution of piperidine in 2 mL of DMF. The reaction mixture was shaken for 5 min, and the solvent was removed by filtration. The resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. The piperidine deblocking step was repeated twice and the resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. An aliquot of the resin was removed, and a qualitative Kaiser free amine test indicated the presence of a free amine. The resin was suspended in a solution of 0.068 g (0.180 mmol) of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 0.150 g (0.180 mmol) of threonine disaccharide 7, 0.027 g (0.180 mmol) of hydroxybenzotriazole (HOBt), and 0.063 mL (0.360 mmol) of N,N-diisopropylethylamine (DIPEA) in 2 mL of DMF. The reaction mixture was shaken for 45 min, and the solvent was removed by filtration. The resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. An aliquot of the resin was removed, and a qualitative Kaiser free amine test indicated the absence of a free amine. An aliquot of the resin was subjected to Fmoc cleavage assay analysis, which indicated a loading of 0.032 mmol/g (corresponding to 42% coupling efficiency). The resin was dried under diminished pressure and carried on to the methylvalerate coupling step: mass spectrum (matrix-assisted laser desorption ionization time-of-flight, MALDI-TOF) m/z 1108.3 (M + H) + (theoretical m/z 1108.3). Resin-Bound Spermine Tetrapeptide. To 0.355 g (loading of 0.032 mmol/g) of swollen tripeptide resin was added a 20% solution of piperidine in 2 mL of DMF. The reaction mixture was shaken for 5 min, and the solvent was removed by filtration. The resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. The piperidine deblocking step was repeated twice and the resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. An aliquot of the resin was removed, and a qualitative Kaiser free amine test indicated the presence of a free amine. The resin was suspended in a solution of 0.021 g (0.057 mmol) of Fmoc-methylvalerate, 39, 40 0.022 g (0.057 mmol) of HBTU, 0.009 g (0.057 mmol) of HOBt, and 0.020 mL (0.114 mmol) of Hunig's base (DIPEA) in 2 mL of DMF. The reaction mixture was stirred for 45 min, and the solvent was removed by filtration. The resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. An aliquot of the resin was removed, and a qualitative Kaiser free amine test indicated the absence of a free amine. An aliquot of the resin was subjected to Fmoc cleavage assay analysis, which indicated a loading of 0.029 mmol/g (corresponding to 94% coupling efficiency). The resin was dried under diminished pressure and carried on to the histidine coupling step: mass spectrum (MALDI-TOF) m/z 1237.4 (M + H) + (theoretical m/z 1237.4). Resin-Bound Spermine Pentapeptide. To 0.350 g (loading of 0.029 mmol/g) of swollen tetrapeptide resin was added a 20% solution of piperidine in 2 mL of DMF. The reaction mixture was shaken for 10 min, and then the solvent was removed by filtration. The resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. The piperidine deblocking step was repeated twice and the resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. An aliquot of the resin was removed, and a qualitative Kaiser free amine test indicated the presence of a free amine. The resin was suspended in a solution of 0.031 g (0.050 mmol) of Fmoc-tritylhistidine, 0.019 g (0.050 mmol) of 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 0.007 g (0.050 mmol) of 1-hydroxy-7-azabenzotriazole (HOAt), and 0.017 mL (0.100 mmol) of Hunig's base in 2 mL of DMF. The reaction mixture was stirred for 45 min, and the solvent was removed by filtration. The resin was washed successively with three 10 mL portions of CH 2 Cl 2 , three 10 mL portions of MeOH, and three 10 mL portions of DMF. An aliquot of the resin was removed, and a qualitative Kaiser free amine test indicated the absence of a free amine. An aliquot of the resin was subjected to Fmoc cleavage assay analysis, which indicated a loading of 0.051 mmol/g. The resin was dried under diminished pressure: mass spectrum (MALDI-TOF) m/z 1616.5 (M + H) + (theoretical m/z 1616.5).
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Deglycobleomycin Analogue 3. To a suspension containing 0.118 g of pentapeptide resin were added three 0.5 mL solutions containing 20% piperidine in DMF for 10 min each. The resulting resin was washed for 30 s each with seven 5 mL portions of DMF, five 5 mL portions of CH 2 Cl 2 , and three 5 mL portions of DMF. The resin was then added to a 10 mL round-bottom flask containing 1 mL of DMF and cooled to 0°C for 10 min. A mixture containing 5.00 mg (11.6 μmol) of Boc-pyrimidoblamic acid 59−61 and 19.0 mg (34.8 μmol) of (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) was added to the resin with an additional 1 mL of DMF. The reaction mixture was cooled for an additional 10 min, followed by the addition of 12 μL (9.0 mg, 70 μmol) of Hunig's base. After 16 h, the resin was filtered and washed for 30 s each with three 5 mL portions of DMF, three 5 mL portions of CH 2 Cl 2 , and three 5 mL portions of MeOH. The resin was dried under vacuum for 2 h. To a suspension containing 0.076 g of resin-bound fully protected deglycoBLM A 6 precursor was added a solution containing 200 μL of triisopropylsilane and 200 μL of methyl sulfide. After 5 min, 4 mL of trifluoroacetic acid (TFA) was added to the suspension. After 4 h, the resin was filtered and washed with five 3 mL portions of CH 2 Cl 2 and three 3 mL portions of DMF. The resulting resin was treated with 0.5 mL of a solution containing 20% hydrazine in DMF. The resin was filtered and then treated with three 0.5 mL portions of 20% hydrazine in DMF for an additional 10 min each. The eluate was collected and concentrated under diminished pressure. The resulting oil was dissolved in 0.1% aqueous CF 3 COOH, frozen, and lyophilized. The crude product was purified on an Alltech Alltima C 18 reversed-phase semipreparative (250 × 10 mm, 5 μm) HPLC column by use of 0.1% aqueous CF 3 Na requires m/z 825.1808). DeglycoBLM Analogue 6. To a solution containing 1.0 mg (1.2 μmol) of 27 and 1.0 mg (0.9 μmol) of Cu(II)·deglycobleomycin A 5 in 0.5 mL of anhydrous DMF was added 5.0 μL (3.7 mg; 36 μmol) of dry triethylamine, and the reaction mixture was shaken at room temperature for 3 h. Fifty microliters (51 mg; 1.6 mmol) of hydrazine was added and the reaction mixture was shaken at room temperature for 1 h and then concentrated under diminished pressure. The reaction mixture was diluted with 0.2 mL of 1:1 0.1% aqueous CF 3 [from Fe(NH 4 ) 2 (SO 4 ) 2 ·6H 2 O] and (deglyco)BLM solutions in a 15 μL reaction mixture (total volume) containing 50 mM Tris-HCl, pH 8.0. Reactions were incubated at 25°C for 30 min and were then quenched by the addition of 3 μL of native gel loading buffer containing 30% glycerol and 0.125% (w/v) bromophenol blue. Five microliters of the reaction mixture was loaded onto a 1% agarose gel containing 9 mM Tris−borate buffer, pH 8.3, and 320 μM disodium ethylenediaminetetraacetate (Na 2 EDTA). The gel was run at 96 V for 2 h in a buffer solution containing 9 mM Tris−borate buffer, pH 8.3, and 320 μM Na 2 EDTA. The gel was then stained in the running buffer solution supplemented with 0.5 μg/mL ethidium bromide for 1 h, followed by destaining in water for 15 min. Gels were then analyzed with a UV transilluminator.
MTT Assay. 64 DU145 (American Type Culture Collection) human prostate cancer cells were grown in log-phase mode in Eagle's minimal essential medium (MEM; Gibco) supplemented with 10% fetal bovine serum and 1% penicillin−streptomycin. Cells were trypsinized and seeded into a 96-well plate in 100 μL of culture medium at 5000 cells/ well. Cells were incubated for 24 h, followed by removal of medium and replacement with medium containing each bleomycin derivative at the appropriate concentration to the wells. The samples contained dimethyl sulfoxide (DMSO) at a final concentration of 5%. Following incubation with each compound for 24 h, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added at a concentration of 5 mg/mL in phosphate-buffered saline, pH 7.4. After incubation for 3 h at 37°C, the culture medium was removed, and the crystals were dissolved in 200 μL of DMSO. The 96-well plate was read in a multiwell plate reader with an absorbance filter of 560 nm and a reference filter of 670 nm. Data were analyzed by the use of QtiPlot for determination of linear fit. supplemented with 10% fetal bovine serum (HyClone, South Logan, UT) and 1% penicillin−streptomycin antibiotic mixture (Cellgro, Manassas, VA). DU145 (ATCC HTB-81) prostate cancer cells, PZ-HPV-7 (ATCC CRL-2221) normal prostate cells, WI-38 (ATCC CCL-75) normal lung cells, and CCD-1105 KIDTr (ATCC CRL-2305) normal kidney cells were grown in MEM medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (HyClone) and 1% penicillin−streptomycin mix antibiotic supplement. The cells were incubated at 37°C under a humidified atmosphere of 5% CO 2 and 95% air.
Fluorescence Microscopy. Fluorescence images were acquired on a Zeiss Axiovert 200 M inverted microscope fitted with an AxioCam MRm camera equipped with a 300 W xenon lamp (Sutter, Novato, CA) and Cy5 and Cy7 cyanine filter (Chroma, Bellows Falls, VT). The cells were grown on 16-well Lab-Tek glass chamber slides at a cell density of 5000 cells/well (Thermo Scientific, Waltham, MA) at 37°C for 48 h. Cells were rinsed twice with phosphate-buffered saline (PBS) and the medium was replaced with RPMI 1640 (no phenol red) when the cell density reached 70% confluence. Cells were treated with dyelabeled conjugates to the final desired concentration. Cells were incubated at 37°C for 1 h, washed with PBS, and then fixed with 4% paraformaldehyde at 37°C for 5 min. Finally, the slide was mounted with Prolong Antifade Gold reagent with DAPI (Invitrogen). All images were recorded and the target cells were counted by use of a 40× oil objective. To ensure accurate intensity measurements, the exposure time and laser time were kept identical. Pixel intensity was quantified by the use of AxioVision Release 4.7 version software, and the mean pixel intensity was generated as gray level. 
